前列环素类似物与肺动脉高压合并糖尿病患者视网膜病变结局的队列分析
这项回顾性真实世界队列研究利用TriNetX全球协作网络进行1:1倾向评分匹配,比较接受含前列环素类似物(PCA)双药治疗的患者与接受内皮素受体拮抗剂、磷酸二酯酶-5抑制剂或可溶性鸟苷酸环化酶刺激剂但不含PCA的匹配对照。在2,584对匹配患者中,PCA治疗与非增殖性糖尿病视网膜病变(DR)和糖尿病伴眼科并发症的发生率显著降低相关,增殖性DR发生率无统计学显著差异。结论提示PCA治疗可能与降低DR发生风险相关。
要点
- PCA治疗与非增殖性DR发生率显著降低相关(HR=0.59,95%CI 0.35-0.97,P=0.0345)。
- PCA治疗与糖尿病伴眼科并发症发生率显著降低相关(HR=0.67,95%CI 0.49-0.91,P=0.0105)。
- 增殖性DR发生率在两组间无统计学显著差异(HR=0.63,95%CI 0.27-1.43,P=0.2617)。
核心结论
- PCA治疗可能与降低糖尿病视网膜病变发生风险相关,提示潜在的系统性微血管保护效应。
- 需进一步前瞻性研究探索PCA在糖尿病相关视网膜疾病中的治疗作用。
研究设计与样本
- 回顾性真实世界队列研究,利用TriNetX全球协作网络进行1:1倾向评分匹配。
- 比较接受含PCA双药治疗的患者与接受内皮素受体拮抗剂、磷酸二酯酶-5抑制剂或可溶性鸟苷酸环化酶刺激剂但不含PCA的匹配对照。
- 排除既往已诊断DR的患者,采用Cox比例风险模型和Kaplan-Meier生存分析评估5年期间结局。
- 两个队列各纳入2,584例匹配患者。
主要发现
- PCA治疗组非增殖性DR事件数为24,对照组为42,HR=0.59(95%CI 0.35-0.97,P=0.0345)。
- PCA治疗组糖尿病伴眼科并发症事件数为65,对照组为99,HR=0.67(95%CI 0.49-0.91,P=0.0105)。
- 增殖性DR事件数PCA组为10,对照组为15,HR=0.63(95%CI 0.27-1.43,P=0.2617),无统计学显著差异。
临床怎么用
- 对于合并肺动脉高压的糖尿病患者,使用含PCA方案时可能需关注其与DR发生风险的潜在关联。
- 目前证据来自回顾性队列,不能据此改变DR筛查或治疗决策,需结合眼科专科评估。
局限性
- 研究为回顾性设计,存在残留混杂可能。
- 结论需前瞻性研究进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The aim of this study was to evaluate the association between prostacyclin analog (PCA) therapy and the long-term incidence of diabetic retinopathy (DR) in patients with diabetes and pulmonary arterial hypertension. METHODS: In this retrospective, real-world cohort study, the authors used 1:1 propensity score matching within the TriNetX Global Collaborative Network to compare patients receiving dual therapy including PCAs versus matched controls treated with endothelin receptor antagonists, phosphodiesterase-5 inhibitors, or soluble guanylate cyclase stimulators without PCAs. Patients with a prior DR diagnosis were excluded. The incidence of nonproliferative DR, proliferative DR, and diabetes with ophthalmic complications was assessed over a 5-year period using Cox proportional hazards models and Kaplan-Meier survival analyses. RESULTS: Among 2,584 matched patients in both cohorts, PCA therapy was associated with a significantly lower incidence of nonproliferative DR (24 vs. 42 events; hazard ratio [HR] = 0.59; 95% confidence interval [CI], 0.35-0.97; P = 0.0345) and diabetes with ophthalmic complications (65 vs. 99 events; HR = 0.67; 95% CI, 0.49-0.91; P = 0.0105). No statistically significant difference was observed in proliferative DR incidence (10 vs. 15 events; HR = 0.63; 95% CI, 0.27-1.43; P = 0.2617). CONCLUSION: PCA therapy may be associated with a reduced risk of developing DR, suggesting potential systemic microvascular protective effects. Further prospective studies are warranted to explore the therapeutic role of PCAs in diabetes-related retinal disease.
引用
- Lishinsky-Fischer N, Levy J. PROSTACYCLIN ANALOGS AND DIABETIC RETINOPATHY OUTCOMES IN PATIENTS WITH PULMONARY HYPERTENSION : A Cohort Analysis. Retina. 2026. PMID: 42308470. doi:10.1097/IAE.0000000000004821
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。